Literature DB >> 16769248

Molecular mechanisms of insulin resistance in polycystic ovary syndrome.

Evanthia Diamanti-Kandarakis1, Athanasios G Papavassiliou.   

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrinopathy of unknown aetiology that affects women of reproductive age. During the past ten years, defective insulin activity in PCOS has been demonstrated in target tissues and causes insulin resistance and hyperinsulinaemia. Furthermore, presence of insulin receptors in the ovarian tissue and overproduction of androgens by theca cells leads to characteristic hyperandrogenaemia. Recent data suggest a divergence in post-receptor signalling pathways for insulin in its target tissues (muscle, adipocytes and ovarian tissue), where the metabolic pathway of insulin activity is defective, whereas the activation of steroidogenesis is maintained. Investigators are still searching for clues to understand the cause of this enigmatic syndrome, despite great advances in molecular medicine and genetics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16769248     DOI: 10.1016/j.molmed.2006.05.006

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  72 in total

1.  Common genetic variation in the 3'-untranslated region of gonadotropin-releasing hormone receptor regulates gene expression in cella and is associated with thyroid function, insulin secretion as well as insulin sensitivity in polycystic ovary syndrome patients.

Authors:  Qiaoli Li; Guizhong Yang; Ying Wang; Xiaoping Zhang; Qing Sang; Huan Wang; Xinzhi Zhao; Qinghe Xing; Lin He; Lei Wang
Journal:  Hum Genet       Date:  2011-01-28       Impact factor: 4.132

Review 2.  Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions.

Authors:  Kristen Farrell; Michael H Antoni
Journal:  Fertil Steril       Date:  2010-05-14       Impact factor: 7.329

Review 3.  The Role of Physical Activity in Preconception, Pregnancy and Postpartum Health.

Authors:  Cheryce L Harrison; Wendy J Brown; Melanie Hayman; Lisa J Moran; Leanne M Redman
Journal:  Semin Reprod Med       Date:  2016-05-11       Impact factor: 1.303

Review 4.  Targets to treat metabolic syndrome in polycystic ovary syndrome.

Authors:  Shruthi Mahalingaiah; Evanthia Diamanti-Kandarakis
Journal:  Expert Opin Ther Targets       Date:  2015-10-21       Impact factor: 6.902

5.  Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance.

Authors:  M C Amato; R Vesco; E Vigneri; A Ciresi; C Giordano
Journal:  J Endocrinol Invest       Date:  2015-08-21       Impact factor: 4.256

6.  Characterization of GAB1 expression over the menstrual cycle in women with and without polycystic ovarian syndrome provides a new insight into its pathophysiology.

Authors:  K L Roemer; S L Young; R F Savaris
Journal:  J Clin Endocrinol Metab       Date:  2014-08-21       Impact factor: 5.958

7.  Changes in the expression of insulin signaling pathway molecules in endometria from polycystic ovary syndrome women with or without hyperinsulinemia.

Authors:  Romina Fornes; Paulina Ormazabal; Carlos Rosas; Fernando Gabler; David Vantman; Carmen Romero; Margarita Vega
Journal:  Mol Med       Date:  2009-12-04       Impact factor: 6.354

Review 8.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

9.  Common genetic variation in CYP1B1 is associated with concentrations of T₄, FT₃ and FT₄ in the sera of polycystic ovary syndrome patients.

Authors:  Shien Zou; Qing Sang; Huan Wang; Ruizhi Feng; Qiaoli Li; Xinzhi Zhao; Qinghe Xing; Li Jin; Lin He; Lei Wang
Journal:  Mol Biol Rep       Date:  2013-01-03       Impact factor: 2.316

10.  Metabolic actions of insulin in ovarian granulosa cells were unaffected by hyperandrogenism.

Authors:  Shidou Zhao; Haijing Xu; Yuqian Cui; Wenting Wang; Yingying Qin; Li You; Wai-Yee Chan; Yun Sun; Zi-Jiang Chen
Journal:  Endocrine       Date:  2016-04-08       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.